


***28th Annual Prostate Cancer Foundation
Scientific Retreat***

***October 28 - 29, 2021
November 4 - 5, 2021***



AGENDA

Thursday, October 28, 2021
***All times in U.S. PDT**

VIRTUAL POSTER SESSION

Starting on Thursday October 28, 2021, 12:01 AM U.S. PDT

GENERAL SESSIONS

Welcome & Opening Remarks

7:00 AM - 7:04 AM

Howard Soule, PhD
Prostate Cancer Foundation

Session 1: Dr. Andrew Hruszkewycz Memorial Session on Measuring and Targeting Lineage Plasticity to Prevent Lethal Prostate Cancer

7:04 AM - 8:30 AM

Moderator: Andrew Armstrong, MD, ScM
Duke University

A Tale of Two Evasions: Lineage Plasticity and Tumor Heterogeneity

Ping Mu, PhD
UT Southwestern Medical Center at Dallas

Measuring CRPC Cellular Heterogeneity at the Single Cell Level to Inform Treatment Strategies

Eliezer Van Allen, MD, PhD
Harvard: Dana-Farber Cancer Institute

Measuring Lineage Plasticity and Heterogeneity in mCRPC with Liquid Biopsies to Inform Treatment

Andrew Armstrong, MD, ScM
Duke University

Thursday, October 28, 2021

Targeting Transformed Neuroendocrine Cells to Overcome Treatment Resistance

Amina Zoubeydi, PhD

Vancouver Prostate Centre, Canada

Followed by Live Session Discussion

8:30 AM - 8:45 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

Session 2: Therapeutic Degradors as a New Class of Prostate Cancer Treatments

8:45 AM - 9:25 AM

Moderator: Howard Soule, PhD

Prostate Cancer Foundation

Targeting Enhancer Addiction in Prostate Cancer by Impeding Chromatin Accessibility

Arul M. Chinnaiyan, MD, PhD

University of Michigan, Michigan Center for Translational Pathology

Clinical Development of ARV-110, a Novel AR Degradar, in Prostate Cancer

Debbie Chirnomas, MD, MPH

Arvinas, Inc.

Followed by Live Session Discussion

9:25 AM - 9:40 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

Session 3: PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment

9:40 AM - 12:00 PM

Moderator: Michael Hofman, MBBS

Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia

LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer

Michael Hofman, MBBS

Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia

Thursday, October 28, 2021

Results from the PRINCE Trial: Testing the Combination of LuPSMA with Pembrolizumab in mCRPC

Shahneen Sandhu, MBBS

Peter MacCallum Cancer Centre, Australia

Targeting Micro-Metastatic Disease with Auger or Alpha Emitters

Ana Kiess, MD, PhD

Johns Hopkins University

The Four Sisters of Terbium: PET & SPECT Imaging and Targeted Alpha- & Beta-Therapy

Cristina Müller, PhD, PD

Paul Scherrer Institute, Switzerland

aPROMISE: An Artificial Intelligence Platform to Assist in Standardizing the Detection, Localization and Quantification of Prostate Cancer in PYLARIFY PSMA Scans

Aseem Anand, PhD

Imaging-Oncology Biomarker, EXINI Diagnostics AB. Sweden (a wholly owned subsidiary of Lantheus Holdings)

Targeting Fibroblast Activation Protein-alpha (FAP) in Prostate Cancer: Is FAP the Next Theranostic Target after PSMA in Prostate Cancer?

Andy Simmons, PhD

Clovis Oncology

Insights & Future Predictions from 25 Years of PSMA Research

Neil Bander, MD

Weill Cornell Medical College

Followed by Live Session Discussion

12:00 PM - 12:15 PM ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

VIRTUAL POSTER SESSION 1

12:15 PM - 1:45 PM

**Come to the Poster Hall for Live Discussions
with Virtual Poster Session 1 Presenters**

PCF DOCTOR-PATIENT SUMMIT: Live from the Scientific Retreat

1:00 PM - 3:00 PM

END DAY

Friday, October 29, 2021

Session 4: Prostate Cancer Disparities

7:00 AM - 8:40 AM

Moderator: Kosj Yamoah, MD, PhD

Moffitt Cancer Center

***Overview on Prostate Cancer Disparities in African Americans:
Lessons from the VA Health System and VANDAAM Study***

Kosj Yamoah, MD, PhD

Moffitt Cancer Center

Isla Garraway, MD, PhD

University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Epidemiologic Aspects of Prostate Cancer in Black Men and Men of African Ancestry

Lorelei Mucci, ScD

Harvard T.H. Chan School of Public Health

Disparities in Metastatic Prostate Cancer and Opportunities to Exploit Biology to Improve Outcomes

Franklin Huang MD, PhD

University of California, San Francisco

Evidence and Solutions in Access with Equitable Health Care as a Contributor to Prostate Cancer Disparities

Brandon Mahal, MD

University of Miami

The Importance of Clinical Trial Diversity & Lessons from the COVID-19 Vaccine Trial

Sandra Amaro, MBA

Pfizer

Followed by Live Session Discussion

8:40 AM - 8:55 AM

BREAK, Please Return to the Virtual Lobby to Join the Next Session

Friday, October 29, 2021

Session 5: Prostate Cancer Survivorship

8:55 AM - 10:45 AM

Moderator: Alicia Morgans, MD, MPH

Harvard: Dana-Farber Cancer Institute

Prostate Cancer Survivorship: New Programs and Strategies

Alicia Morgans, MD, MPH

Harvard: Dana-Farber Cancer Institute

Updates and Preliminary Results from the PCF-SURECaP Survivorship Working Group Initiatives: COGCaP and ARACOG

Charles J. Ryan, MD

University of Minnesota; Prostate Cancer Foundation

Sleep Dysfunction and Prostate Cancer

Stacy Loeb, MD, MSc, PhD (Hon)

New York University; Manhattan Veterans Affairs Hospital

Utilization of an "Exercise is Medicine" Approach to Optimize Treatment and Health Outcomes among Prostate Cancer Survivors

Christina Dieli-Conwright, PhD, MPH

Harvard: Dana-Farber Cancer Institute

Prostate Cancer Survivorship at the VA: Leveraging Existing Veterans' Data to Improve Cardiovascular and Bone Health

Ravi Parikh, MD, MPP

University of Pennsylvania; The Corporal Michael J. Crescenzo VA Medical Center

Patient Perspective - ADT, Exercise and QoL

Joël Pointon, MPH

Patient and Advocate

Followed by Live Session Discussion

Special Lecture: ADT and CV Risk: Why Relugolix?

10:45 AM - 11:05 AM

Neal Shore, MD

Carolina Urologic Research Center

GenesisCare, US

Introduced and Moderated by Howard Soule, PhD

Prostate Cancer Foundation

Followed by Live Discussion

Friday, October 29, 2021

11:05 AM - 11:20 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

Session 6: Predicting Risk of Prostate Cancer with Polygenic Scores

11:20 AM - 12:20 PM

Moderator: Tyler Seibert, MD, PhD
University of California, San Diego

Genetic Risk Prediction for Prostate Cancer

Christopher Haiman, ScD
University of Southern California

Genetic Risk Stratification for Prostate Cancer: Genomics, Ancestry, and Disparities

Tyler Seibert, MD, PhD
University of California, San Diego

A Healthy Lifestyle in Men with a High Prostate Cancer Polygenic Risk Score

Anna Plym, PhD
Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health

Followed by Live Session Discussion

12:20 PM - 12:30 PM ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

VIRTUAL POSTER SESSION 2

12:30 PM - 2:00 PM

**Come to the Poster Hall for Live Discussions
with Virtual Poster Session 2 Presenters**

END DAY

Thursday, November 4, 2021

Session 7: Next Generation Precision Medicine

7:00 AM - 8:10 AM

Moderator: Felix Feng, MD
University of California, San Francisco

A Multi-Omic Perspective on mCRPC

Felix Feng, MD
University of California, San Francisco

Using Genomics and Histopathology to Understand Therapeutic Responses in Prostate Cancer

Joel Greshock
Janssen Oncology

Lessons from Esophageal Cancer Genomics

Rebecca Fitzgerald, PhD
University of Cambridge, United Kingdom

Followed by Live Session Discussion

8:10 AM - 8:25 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

PCF WOMEN IN SCIENCE AWARD LECTURE: Tumor Suppressors Reimagined: Converting Understanding of RB Action into Translational Potential

8:25 AM - 9:10 AM

Karen Knudsen, MBA, PhD
American Cancer Society

*Introduced and moderated by Andrea Miyahira, PhD and Howard Soule, PhD
Prostate Cancer Foundation*

Followed by Live Discussion

Thursday, November 4, 2021

KEYNOTE ADDRESS

9:10 AM - 10:10 AM

Michael Milken

Founder and Chairman
Prostate Cancer Foundation

*Introduced by Stuart Holden, MD
Prostate Cancer Foundation*

10:10 AM - 10:25 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

SPECIAL LECTURE: Oncology: A Storied Past and Portentous Future

10:25 AM - 11:00 AM

Anna Barker, PhD

Lawrence J. Ellison Institute for Transformative Medicine of the University of
Southern California

*Introduced and moderated by Howard Soule, PhD
Prostate Cancer Foundation*

Followed by Live Discussion

SPECIAL LECTURE

11:00 AM - 11:40 AM

PCF 3.0: Serving the Science, the Scientist and the Patient

Charles J. Ryan, MD

Prostate Cancer Foundation

*Introduced and moderated by Howard Soule, PhD
Prostate Cancer Foundation*

Followed by Live Discussion

Thursday, November 4, 2021

Session 8: Glucocorticoid Receptor Biology in Castration Resistant Prostate Cancer

11:40 AM -12:40 PM

Moderator: Nima Sharifi, MD
Cleveland Clinic

Acquired Defects in Glucocorticoid Metabolism in Enzalutamide-Resistant Prostate Cancer

Nima Sharifi, MD
Cleveland Clinic

Targeting the Glucocorticoid Receptor Pathway in CRPC

Suzanne D. Conzen, MD
UT Southwestern Medical Center

Diverse Roles of the Androgen Receptor in Breast and Prostate Cancer

Wayne Tilley, PhD
University of Adelaide, Australia

Followed by Live Session Discussion

12:40 PM - 1:00 PM ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

VIRTUAL POSTER SESSION 3

1:00 PM - 2:30 PM

**Come to the Poster Hall for Live Discussions
with Virtual Poster Session 3 Presenters**

END DAY

Friday, November 5, 2021

Session 9: Real World Evidence and Synthetic/Virtual Control Arms

7:00 AM - 8:00 AM

Moderator: Julie Lynch, PhD, RN, MBA

VINCI Precision Medicine, Salt Lake City VA & University of Utah

Opportunities and Pitfalls of Conducting Prostate Cancer Research using Big Data in the VA

Julie Lynch, PhD, RN, MBA

VINCI Precision Medicine, Salt Lake City VA & University of Utah

Analysis of the VA Prostate Cancer Data: A Valuable Resource that can now be Leveraged by Everyone

Tito Fojo, MD, PhD

Columbia University and the James J. Peters VAMC

Using Real World Evidence to Drive Stakeholder Decisions in Oncology

Michael Spencer, MSc

Janssen Oncology

Followed by Live Session Discussion

Special Lecture: Tumor Metabolism as a Driver and Treatment Target in Prostate Cancer

8:00 AM - 8:35 AM

Massimo Loda, MD

Weill Cornell Medicine

Introduced and moderated by Howard Soule, PhD

Prostate Cancer Foundation

Followed by Live Discussion

8:35 AM - 8:50 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

Session 10: Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer

8:50 AM - 10:35 AM

Moderator: Amy Moran, PhD

Oregon Health & Science University

Friday, November 5, 2021

A T Cell Intrinsic Role for Androgen Receptor Signaling and Immunotherapy Resistance

Amy Moran, PhD

Oregon Health & Science University

Checkpoint Immunotherapy in mCRPC with CDK12-Loss

Ajjai Alva, MD

University of Michigan

MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With mCRPC: Preliminary Results of Phase 1 Cohort Expansion

Chet Bohac, PharmD, MD, MSc

MacroGenics, Inc.

Targeting DLL3 with a Bi-Specific T Cell Engager: AMG 757 in De Novo and Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Rahul Aggarwal, MD

University of California, San Francisco

Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer

Oliver Sartor, MD

Tulane University

Followed by Live Session Discussion

10:35 AM - 10:50 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

Session 11: Novel Technologies to Overcome the Suppressive Tumor Microenvironment

10:50 AM - 12:15 PM

Moderator: Marco Gottardis, PhD

Janssen Research & Development, LLC

Introduction

Marco Gottardis, PhD

Janssen Research & Development, LLC

Improving CAR Responses against Solid Tumors with Conditional Payload Delivery

Gus Zeiner, PhD

Chimera Bioengineering

Friday, November 5, 2021

Combining Adenosine Pathway Inhibitors with Immunotherapy Agents in Prostate Cancer

Peter Fan, PhD

Teon Therapeutics

Mobilizing the Immune System with Bispecific Antibodies and Optimized Cytokines

John Desjarlais, PhD

Xencor

Microenvironment on Demand (MOD) – A Flexible Droplet-Microfluidic Platform to Accelerate Cell/Antibody Therapy Discoveries

Maithreyan Srinivasan, PhD

Scribe Biosciences

Followed by Live Session Discussion

Closing Remarks

12:15 PM - 12:20 PM


Howard Soule, PhD

Prostate Cancer Foundation

Andrea Miyahira, PhD

Prostate Cancer Foundation

Meeting Adjourned



Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation)

Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Andrew Armstrong, MD, ScM (Duke University)

Paul Boutros, PhD (University of California, Los Angeles)

Marco Gottardis, PhD (Janssen Research & Development, LLC)

Michael Hofman, MBBS (Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia)

Alicia Morgans, MD, MPH (Harvard: Dana-Farber Cancer Institute)

Nima Sharifi, MD (Cleveland Clinic)

Kosj Yamoah, MD, PhD (Moffitt Cancer Center)

Times subject to small changes based on the final event production. All times in U.S. PDT.

We deeply thank our Retreat supporters for providing funding for this educational initiative.

